HKEX

Summit Therapeutics Announces Updated Phase II Data for Ivonescimab at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024

The aforementioned data related to AK112-201 was generated and analyzed by Akeso.

Key Points: 
  • The aforementioned data related to AK112-201 was generated and analyzed by Akeso.
  • Both studies represent ivonescimab in randomized, pivotal clinical trials against the standard of care in their respective settings.
  • “As the data continues to mature in Phase II studies evaluating ivonescimab, including data related to the survival of patients impacted by these terrible diseases, our belief and conviction in ivonescimab is reinforced,” stated Summit’s Chief Executive Officers, Robert W. Duggan and Dr. Maky Zanganeh.
  • We believe that the potential created by the differentiated mechanism of action and supporting trial data for ivonescimab deserves a swift development plan to bring ivonescimab to those patients who can benefit most.

Biocytogen Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma

Retrieved on: 
Monday, January 8, 2024

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics, today announces that it has entered into an Exclusive Option and License Agreement with Radiance Biopharma Inc. (“Radiance”), a biotechnology company specializing in developing next generation Antibody Drug Conjugates.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics, today announces that it has entered into an Exclusive Option and License Agreement with Radiance Biopharma Inc. (“Radiance”), a biotechnology company specializing in developing next generation Antibody Drug Conjugates.
  • The agreement grants Radiance an option to license from Biocytogen a first-in-class fully human anti-HER2/TROP2 bispecific antibody-drug conjugate (BsADC) for therapeutic product development, manufacturing and commercialization for all human indications worldwide.
  • In addition, Biocytogen has the right to collect the sharing of sublicensing fee, if any, between Radiance and third party.
  • Dr. Yuelei Shen, President and CEO of Biocytogen, said: “We are excited to collaborate with Radiance, a strong team with extensive experience in drug development, to develop a leading proprietary fully human bispecfic antibody drug conjugate.

NIO Inc. Announces Repurchase Right Notification for 0.00% Convertible Senior Notes due 2026

Retrieved on: 
Wednesday, January 3, 2024

The Repurchase Right expires at 5:00 p.m., New York City time, on Wednesday, January 31, 2024.

Key Points: 
  • The Repurchase Right expires at 5:00 p.m., New York City time, on Wednesday, January 31, 2024.
  • The Repurchase Right entitles each holder of the Notes to require the Company to repurchase all of such holder’s Notes or any portion thereof that is an integral multiple of US$1,000 principal amount.
  • If all outstanding Notes are surrendered for repurchase through exercise of the Repurchase Right, the aggregate cash purchase price will be US$301,448,000.00.
  • In order to exercise the Repurchase Right, a holder must follow the transmittal procedures set forth in the Company’s Repurchase Right Notice to holders (the “Repurchase Right Notice”), which is available through the Depository Trust Company and The Deutsche Bank Trust Company Americas.

Tencent Music Entertainment Group and Universal Music Group Extend Multi-year Strategic Licensing Agreement

Retrieved on: 
Wednesday, January 3, 2024

SHENZHEN, China, Jan. 3, 2024 /PRNewswire/ -- Tencent Music Entertainment Group ("TME," or the "Company") (NYSE: TME and HKEX: 1698), the leading online music and audio entertainment platform in China, and Universal Music Group ("UMG"), the world's leading music-based entertainment company, today announced the renewal of a multi-year strategic licensing agreement, fortifying their shared commitment to creating value for artists and exceptional experiences for music lovers.

Key Points: 
  • SHENZHEN, China, Jan. 3, 2024 /PRNewswire/ -- Tencent Music Entertainment Group ("TME," or the "Company") (NYSE: TME and HKEX: 1698), the leading online music and audio entertainment platform in China, and Universal Music Group ("UMG"), the world's leading music-based entertainment company, today announced the renewal of a multi-year strategic licensing agreement, fortifying their shared commitment to creating value for artists and exceptional experiences for music lovers.
  • Under the agreement, TME continues to have access to UMG's music catalogue for QQ Music, Kugou Music, Kuwo Music, and WeSing.
  • Adam Granite, UMG's EVP of Market Development, said, "We are pleased to extend our licensing agreement with TME for the Chinese market.
  • UMG will continue to work with TME to bring the very best in music to these passionate music consumers, and to explore new ways to enhance their listening experiences."

H World Group Limited Announces the Change of Officers

Retrieved on: 
Tuesday, January 2, 2024

Mr. Zou has over 30 years of experience in financial management and capital markets in the U.S., Europe and China.

Key Points: 
  • Mr. Zou has over 30 years of experience in financial management and capital markets in the U.S., Europe and China.
  • Prior to joining H World, Mr. Zou worked as the chief financial officer of Shenzhen Qiqitong Technology Co., Ltd., a one-stop digital sourcing management platform.
  • Since joining H World, he has demonstrated solid capabilities and leadership in response to our evolving business.
  • We are certain that Jun is the right candidate to serve as our new chief financial officer, and together with our core management team, will help lead H World to its next success.

XPENG Launches X9 Ultra Smart Large Seven-seater in China

Retrieved on: 
Monday, January 1, 2024

GUANGZHOU, China, Jan. 01, 2024 (GLOBE NEWSWIRE) -- XPeng Inc. (“XPENG” or the “Company,” NYSE: XPEV and HKEX: 9868), a leading Chinese smart electric vehicle (“Smart EV”) company, announced today the official launch of the XPENG X9 large 7-seater MPV, a flagship model built on its next-generation technology architecture SEPA2.0, for the Chinese market.

Key Points: 
  • GUANGZHOU, China, Jan. 01, 2024 (GLOBE NEWSWIRE) -- XPeng Inc. (“XPENG” or the “Company,” NYSE: XPEV and HKEX: 9868), a leading Chinese smart electric vehicle (“Smart EV”) company, announced today the official launch of the XPENG X9 large 7-seater MPV, a flagship model built on its next-generation technology architecture SEPA2.0, for the Chinese market.
  • Empowered by the cutting-edge SEPA2.0 architecture, the XPENG X9 redefines the conventional norms of MPV models in the market.
  • “With the launch of the XPENG X9, XPENG enriches its Smart EV portfolio, appealing to the primary market needs and promoting the adoption of autonomous driving,” said He Xiaopeng, CEO and Chairman of XPENG.
  • In 2023, XPENG unveiled the next-gen Smart EV architecture, SEPA2.0, and launched one new Smart EV model and three Smart EV model facelift versions.

XPENG Announces Vehicle Delivery Results for December and Fourth Quarter 2023

Retrieved on: 
Monday, January 1, 2024

Deliveries in December 2023 reached a new record of 20,115 units, a 78% increase year-over-year

Key Points: 
  • Deliveries in December 2023 reached a new record of 20,115 units, a 78% increase year-over-year
    60,158 units delivered in Q4 2023, a 171% increase year-over-year
    141,601 units delivered for the full year of 2023, a 17% increase year-over-year
    GUANGZHOU, China, Jan. 01, 2024 (GLOBE NEWSWIRE) -- XPeng Inc. (“XPENG” or the “Company,” NYSE: XPEV and HKEX: 9868), a leading Chinese smart electric vehicle (“Smart EV”) company, today announced its vehicle delivery results for December and the fourth quarter 2023.
  • In December 2023, XPENG delivered 20,115 Smart EVs, a new record for monthly deliveries, representing a 78% increase year-over-year.
  • Fourth quarter 2023 total vehicle deliveries hit 60,158, exceeding 60,000 quarterly deliveries for the first time and marking a 171% increase year-over-year.
  • Total annual deliveries in 2023 reached 141,601 units, a 17% increase over the prior year.

NIO Inc. Provides December, Fourth Quarter and Full Year 2023 Delivery Update

Retrieved on: 
Monday, January 1, 2024

NIO delivered 18,012 vehicles in December 2023, increasing by 13.9% year-over-year

Key Points: 
  • NIO delivered 18,012 vehicles in December 2023, increasing by 13.9% year-over-year
    NIO delivered 50,045 vehicles in the three months ended December 2023, increasing by 25.0% year-over-year
    NIO delivered 160,038 vehicles in 2023 in total, increasing by 30.7% year-over-year
    Cumulative deliveries of NIO vehicles reached 449,594 as of December 31, 2023
    SHANGHAI, China, Jan. 01, 2024 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the premium smart electric vehicle market, today announced its December, fourth quarter and full year 2023 delivery results.
  • NIO delivered 50,045 vehicles in the fourth quarter of 2023, representing an increase of 25.0% year-over-year.
  • For the year of 2023, NIO delivered a total of 160,038 vehicles, showing a year-over-year increase of 30.7%.
  • At NIO Day 2023, NIO launched the ET9, a smart electric executive flagship.

Persistence Resources Announces Details of Proposed Listing on the Main Board of HKEX

Retrieved on: 
Thursday, December 14, 2023

HONG KONG, Dec 14, 2023 - (ACN Newswire) - Persistence Resources Group Ltd. ("Persistence Resources" or the "Group"), the third largest gold miner(1) in Shandong Province, China, has announced the details of the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited ("HKEX") under the stock code 02489.

Key Points: 
  • HONG KONG, Dec 14, 2023 - (ACN Newswire) - Persistence Resources Group Ltd. ("Persistence Resources" or the "Group"), the third largest gold miner(1) in Shandong Province, China, has announced the details of the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited ("HKEX") under the stock code 02489.
  • Trading in the shares of Persistence Resources is expected to commence on the Main Board of the HKEX on 22 December 2023 (Friday) under the stock code 02489.
  • The Group owns two gold mines in the Muping-Rushan gold metallogenic belt in Shandong Province, a major gold producing province.
  • Persistence Resources is led by Dr. SHAO Xuxin, its Chairman, Executive Director and Chief Executive Officer.

Noah Holdings Posts Solid Q3 Financial Performance as Global Expansion Gains Momentum

Retrieved on: 
Thursday, November 30, 2023

Amid global market uncertainty and instability in the Chinese wealth management industry, Noah grew both net revenues and non-GAAP net income on a year-on-year basis during the quarter.

Key Points: 
  • Amid global market uncertainty and instability in the Chinese wealth management industry, Noah grew both net revenues and non-GAAP net income on a year-on-year basis during the quarter.
  • The robust performance was driven by Noah?s reputation for offering prudent and compliant asset allocation solutions as well as its expansion in key overseas hubs to meet demand for global exposure among Chinese high-net-worth investors.
  • In the domestic business, Noah continued to focus on expanding its presence in first-tier cities and other major population centers.
  • Internationally, Noah hit another milestone in its global expansion with the opening of its client service center in Los Angeles.